BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
April 20 2023 - 7:00AM
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or
the "Company"), a digital technology company using machine learning
to usher in a new era of precision medicine, today announced a
strategic partnership with the Sage Group (www.sagehealthcare.com),
a leader in the provision of strategic and transactional advice to
healthcare and life science companies in the pharmaceutical,
diagnostics, medical device, biotech, regenerative medicine, and
cell and gene therapy fields.
The engagement will focus on seeking joint
venture (JV) opportunities to further advance BullFrog AI’s Phase 2
ready asset targeting glioblastoma, an aggressive form of brain
cancer, as well as the Company’s preclinical prodrug asset. The
partnership will give BullFrog AI access to the Sage Group’s
clinical and regulatory expertise, capital resources, and network
of contacts, including innovators and large pharma.
"Glioblastoma is one of the deadliest forms of
cancer, with a five-year survival rate of less than seven percent,”
said BullFrog AI’s founder and CEO, Vin Singh. “With the Sage
Group’s support, we look forward to identifying the right partner
to help us advance clinical development of our oncology programs
globally in an effort to bring a revolutionary new treatment option
to glioblastoma patients.”
The market for glioblastoma treatment is
expected to surpass $10 billion by 2030, up from $5.1 billion in
2020, according to a 2022 analysis by a Vision Research Report.
BullFrog AI has previously announced the grant of exclusive
licenses from JHU for a novel formulation of mebendazole that has
been evaluated in two clinical trials for glioblastoma, and for a
novel prodrug of mebendazole with improved bioavailability.
About BullFrog AI
BullFrog AI is a digital technology company
using machine learning to usher in a new era of precision medicine.
Through its collaborations with leading research institutions,
including Johns Hopkins University, BullFrog AI is at the forefront
of AI-driven drug development. Using its proprietary bfLEAP™
artificial intelligence platform, BullFrog AI aims to enable the
successful development of pharmaceuticals and biologics by
predicting which patients will respond to therapies in development.
BullFrog AI is deploying bfLEAP™ for use at several critical stages
of development with the intention of streamlining data analytics in
therapeutics development, decreasing the overall development costs
by decreasing failure rates for new therapeutics, and impacting the
lives of countless patients that may seek to receive the therapies
they need.
For more information visit BullFrogAI at
Website: www.bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking
statements. We base these forward-looking statements on our
expectations and projections about future events, which we derive
from the information currently available to us. Such
forward-looking statements relate to future events or our future
performance, including: our financial performance and projections;
our growth in revenue and earnings; and our business prospects and
opportunities. You can identify forward-looking statements by those
that are not historical in nature, particularly those that use
terminology such as "may," "should," "expects," "anticipates,"
"contemplates," "estimates," "believes," "plans," "projected,"
"predicts," "potential," or "hopes" or the negative of these or
similar terms. In evaluating these forward-looking statements, you
should consider various factors, including: our ability to change
the direction of the Company; our ability to keep pace with new
technology and changing market needs; and the competitive
environment of our business. These and other factors may cause our
actual results to differ materially from any forward-looking
statement. Forward-looking statements are only predictions. The
forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives, may
not occur, and actual events and results may differ materially and
are subject to risks, uncertainties, and assumptions about us. We
are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
Media Contacts:
BullFrog AI
Dave GentryRedChip Companies,
Inc.BFRG@redchip.com800-733-2447
SOURCE: BullFrog AI Holdings,
Inc.
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jul 2023 to Jul 2024